NewS Archive

Seattle biotech startup born out of a Roche buyout lands $93M to advance therapies

After $250M Roche buyout, a startup plans a second strike with fresh funding

From Good to Great: Bonum Therapeutics Raises $93M Series A with Allosterically Regulated Medicines

The crew that sold its lead IL-2 program to Roche is back with $93M to work on more next-gen I/O drugs

Roche-backed Bonum bags $93M series A to develop new class of conditionally active therapies

Good Therapeutics’ Offshoot Bonum Launches with $93 Million in Series A (Updated)

Good Therapeutics’ Offshoot Bonum Launches with $93 Million in Series A (Updated)

Roche-backed Bonum bags $93M series A to develop new class of conditionally active therapies

Healthcare Investor Digitalis Ventures Nets $300 Million Fund